Summit Therapeutics Inc. (SMMT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Summit Therapeutics Inc. (SMMT) Healthcare & Pipeline Overview

Summit Therapeutics Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel medicines targeting infectious diseases, particularly Clostridioides difficile infection (CDI). Their lead candidate, ridinilazole, is currently in Phase III clinical trials, positioning them to address a significant unmet need in the healthcare sector.

What Is the Investment Thesis for SMMT?

With Phase III clinical trials underway, positive results could drive significant value creation. The company's focus on addressing antibiotic resistance, particularly through SMT-738, aligns with growing global health concerns. However, the success of Summit Therapeutics hinges on the successful completion of clinical trials, regulatory approvals, and effective commercialization strategies. The current market capitalization of $13.8B reflects investor optimism, but the negative beta of -1.37 indicates sensitivity to market volatility. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the company's long-term potential.

Based on FMP financials and quantitative analysis

SMMT Key Highlights

Lead product candidate ridinilazole is in Phase III clinical trials for Clostridioides difficile infection (CDI).

• Focus on combating multidrug-resistant infections with SMT-738, addressing a critical global health need.
• Market capitalization of $13.8B reflects investor confidence in the company's pipeline.
• Negative beta of -1.37 indicates lower correlation with overall market movements.
• Founded in 2003, Summit Therapeutics has a history of developing innovative therapies for infectious diseases.

Who Are SMMT's Competitors?

SMMT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SMMT's Key Strengths?

Lead product candidate in Phase III clinical trials.

• Focus on addressing antibiotic resistance.
• Experienced management team.
• Strong intellectual property portfolio.

What Are SMMT's Weaknesses?

Reliance on a single lead product candidate.

• High R&D expenses.
• Limited commercialization experience.
• Negative beta indicates higher volatility.

What Could Drive SMMT Stock Higher?

Data readout from Phase III clinical trials for ridinilazole.

• Regulatory submissions for marketing approval of ridinilazole.
• Progress in the development of SMT-738 for multidrug-resistant infections.
• Expansion of strategic partnerships and collaborations.

What Are the Key Risks for SMMT?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for ridinilazole.
• Clinical trial failures or delays.
• Competition from other pharmaceutical companies.
• High R&D expenses and cash burn.
• Dependence on key personnel.

What Are the Growth Opportunities for SMMT?

• Successful Completion of Phase III Trials for Ridinilazole: The successful completion of Phase III clinical trials for ridinilazole represents a significant growth opportunity for Summit Therapeutics. Positive trial results would pave the way for regulatory approval and commercialization, potentially capturing a significant share of the CDI treatment market. Timeline: Anticipated data readout and regulatory submissions within the next 12-24 months.
• Expansion into New Geographic Markets: Expanding commercial operations into new geographic markets, particularly in Europe and Asia, presents another growth opportunity. CDI is a global health concern, and introducing ridinilazole in these regions could drive significant revenue growth. This expansion would require strategic partnerships, regulatory approvals, and investment in sales and marketing infrastructure. Timeline: Potential expansion within the next 3-5 years, contingent on regulatory approvals and market access.
• Development of SMT-738 for Multidrug-Resistant Infections: The development of SMT-738 for combating multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae, addresses a critical unmet need in the healthcare sector. Successful development and commercialization of SMT-738 could position Summit Therapeutics as a leader in the fight against antibiotic resistance. The market for treatments targeting multidrug-resistant infections is expected to grow significantly due to the increasing prevalence of these infections. Timeline: Ongoing preclinical and clinical development, with potential market entry in 5-7 years.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical companies and research institutions can accelerate the development and commercialization of Summit Therapeutics' pipeline. These partnerships can provide access to additional funding, expertise, and market access. Collaborations can also help to expand the company's pipeline and diversify its product portfolio. Timeline: Ongoing efforts to establish strategic partnerships and collaborations.
• Acquisition of Complementary Technologies and Assets: Acquiring complementary technologies and assets, such as novel drug delivery systems or diagnostic tools, can enhance Summit Therapeutics' competitive position and expand its capabilities. These acquisitions can provide access to new markets, technologies, and expertise. Strategic acquisitions can also help to diversify the company's pipeline and reduce its reliance on a single product candidate. Timeline: Ongoing evaluation of potential acquisition targets.

What Threats Does SMMT Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established pharmaceutical companies.
• Changes in healthcare policies and reimbursement.

What Are SMMT's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Clinical trial data demonstrating efficacy and safety.
• Specialized expertise in infectious disease treatment.
• Established relationships with key opinion leaders and healthcare providers.

What Does SMMT Do?

Founded in 2003 and headquartered in Cambridge, Massachusetts, Summit Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative medicines aimed at treating infectious diseases. The company's primary focus is on Clostridioides difficile infection (CDI), a severe infection of the colon. Their lead product candidate, ridinilazole, is an orally administered small molecule antibiotic currently undergoing Phase III clinical trials for the treatment of CDI. Ridinilazole represents a potential advancement in CDI treatment due to its novel mechanism of action and promising clinical trial results. Beyond ridinilazole, Summit Therapeutics is also developing SMT-738, which targets multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae infections. Additionally, the company is advancing the DDS-04 series for potential treatment of infections caused by Enterobacteriaceae. Summit Therapeutics operates primarily in the United States and Latin America, conducting clinical programs and seeking regulatory approvals to bring its innovative therapies to market. The company's strategy involves rigorous clinical development, strategic partnerships, and a commitment to addressing critical unmet needs in infectious disease treatment.

What Products and Services Does SMMT Offer?

• Discovers and develops medicines for infectious diseases.
• Focuses on Clostridioides difficile infection (CDI) treatment.
• Conducts Phase III clinical trials for ridinilazole.
• Develops SMT-738 for multidrug-resistant infections.
• Offers DDS-04 series for Enterobacteriaceae infections.
• Commercializes medicines in the United States and Latin America.

How Does SMMT Make Money?

• Develops and patents novel pharmaceutical products.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approvals from agencies like the FDA.
• Commercializes approved products through sales and marketing efforts.

What Industry Does SMMT Operate In?

Summit Therapeutics operates within the biotechnology industry, which is characterized by high innovation, significant regulatory hurdles, and substantial investment in research and development. The market for infectious disease treatments is driven by the increasing prevalence of antibiotic-resistant bacteria and the need for novel therapies. Competitors such as Revolution Medicines, Inc. (RVMD), Royalty Pharma plc (RPRX), and Moderna, Inc. (MRNA) are also active in the biotechnology space, focusing on different therapeutic areas and approaches. Summit Therapeutics' focus on CDI and multidrug-resistant infections positions it to capitalize on the growing demand for targeted therapies in this sector.

Who Are SMMT's Key Customers?

• Hospitals and healthcare providers treating patients with CDI.
• Patients suffering from Clostridioides difficile infection.
• Pharmacies dispensing prescribed medications.
• Healthcare systems and managed care organizations.

Summit Therapeutics Inc. Financial Trajectory

Summit Therapeutics Inc. (SMMT) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $215.7M, with diluted EPS of $-0.28. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SMMT averaged $-0.28 in diluted EPS.

Company Profile

Summit Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Robert W. Duggan. SMMT has traded publicly since 2015.

How Summit Therapeutics Inc. Is Valued

Summit Therapeutics Inc. carries a market capitalization of $13.8B, placing it in the large-cap category. Analyst price targets span from $11.90 to $38.00, with a consensus of $24.99. At the current price of $17.26, that implies approximately 45% upside potential. Relative to its peer group, SMMT's quantitative score of 53/100 is below the peer average of 70/100.

Key Financial Metrics

Its free cash flow yield is -2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.3%, the inverse of the P/E and a quick read on earnings relative to price.

Summit Therapeutics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 41.47 places it in the safe zone, indicating low near-term bankruptcy risk.

Summit Therapeutics Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 122.4% below estimates on average.

Over the past six months, Summit Therapeutics Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 7.9M shares acquired (about $103.6M) — insiders putting money in tends to read as conviction.

SMMT Financials

SMMT Latest News

SMMT Analyst Consensus

SMMT MoonshotScore

Summit Therapeutics Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources